Anzeige
Meldung des Tages: Diese Goldaktie startet NI-43-101 Ressourcenschätzung – jetzt kann aus der Story Substanz werden

Regenxbio Aktie News

Aktie
WKN:  A140E0 ISIN:  US75901B1070 US-Symbol:  RGNX Branche:  Biotechnologie Land:  USA
9,225 €
+0,025 €
+0,27%
07:11:57 Uhr
Depot/Watchlist
Marktkapitalisierung *
602,52 Mio. €
Streubesitz
8,44%
KGV
-1,73
Index-Zuordnung
-

Regenxbio News

28.01.26 - PR Newswire
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs PR Newswire
11.01.26 - PR Newswire
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program PR Newswire
18.12.25 - PR Newswire
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
25.11.25 - PR Newswire
REGENXBIO to Participate in Upcoming Investor Conference
REGENXBIO to Participate in Upcoming Investor Conference PR Newswire
06.11.25 - PR Newswire
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights PR Newswire
30.10.25 - PR Newswire
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program PR Newswire
29.10.25 - PR Newswire
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights PR Newswire
15.10.25 - PR Newswire
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire
09.10.25 - PR Newswire
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting PR Newswire
06.10.25 - PR Newswire
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD PR Newswire
29.09.25 - PR Newswire
REGENXBIO Announces Presentation at the World Muscle Society
REGENXBIO Announces Presentation at the World Muscle Society PR Newswire
05.09.25 - PR Newswire
REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II
REGENXBIO Presents Positive Twelve-​Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II PR Newswire
28.08.25 - PR Newswire
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire
18.08.25 - PR Newswire
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II PR Newswire
07.08.25 - PR Newswire
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights PR Newswire
07.08.25 - PR Newswire
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy PR Newswire
31.07.25 - PR Newswire
REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights
REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights PR Newswire
10.07.25 - PR Newswire
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for ...
05.06.25 - PR Newswire
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 PR Newswire
02.06.25 - PR Newswire
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 PR Newswire

Newssuche

Videos

newspaper
27.01.26 +3,71%
Technical Trading: Pfund Short
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »